Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313752 | 0.83 | CA12 (0.40) | CA12CA14CA1CA7CA2 | |
| SCHEMBL4187258 | 0.83 | CA12 (0.43) | CA12CA14CA1CA7CA2 | |
| SCHEMBL6124841 | 0.75 | CA12 (0.44) | CA12CA14CA1CA7CA2 | |
| SCHEMBL8287306 | 0.73 | CA12 (0.42) | CA12CA14CA1CA7CA2 | |
| SCHEMBL4180962 | 0.73 | CA12 (0.42) | CA12CA14CA1CA7CA2 | |
| SCHEMBL28827505 | 0.72 | CA12 (0.45) | CA12CA14CA1CA7CA2 | |
| SCHEMBL4214454 | 0.72 | CA12 (0.41) | CA12CA14CA1CA7CA2 | |
| SCHEMBL4212292 | 0.72 | CA12 (0.42) | CA12CA14CA1CA7CA2 | |
| SCHEMBL12396882 | 0.72 | CA12 (0.49) | CA12CA14CA1CA7CA2 | |
| SCHEMBL13798315 | 0.71 | CA12 (0.46) | CA12CA14CA1CA7CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | CA12 3950/4885CA14 2467/4885CA1 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.